You need to enable JavaScript to run this app.
Recon: FDA Rejects Motif Bio Antibiotic; AstraZeneca Drops MedImmune Name in R&D Restructuring
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher